Answers are grounded in this paper and cite their sources.
Alpha mangostin (AM) is a natural substance that is thoroughly studied for its pharmacological effects as a potential treatment. Consequently, the safety aspects of AM are important in the development of new pharmaceutical candidates. Despite a comprehensive study of its pharmacological properties, there is limited evidence regarding the safety profile of pure AM administration, particularly by parenteral injection. This study assessed the subchronic intraperitoneal (i.p.) toxicity of AM in Sprague-Dawley rats to determine the No Observed Adverse Effect Level (NOAEL). The subchronic investigation was conducted on both male and female rats by providing varying doses of AM—25, 50, and 100 mg/kg, or DMSO (control)—for a duration of 48 days (terminated early). The subchronic investigation unexpectedly demonstrated significant indicators of toxicity. All AM-treated groups exhibited hemorrhagic ascites, a phenomenon that has not been previously seen following repeated administration of AM. Aspartate aminotransferase (AST) levels in male and female rats showed a slight increase that was not statistically significant compared with the control group. The blood urea nitrogen (BUN) levels in female rats administered 50 mg/kg were considerably elevated compared to the control group. Histological examination revealed significant damage to the livers and kidneys of all AM-treated rats, regardless of sex. These findings indicate that the daily intraperitoneal injection of AM may induce toxicity in rats, and no NOAEL was identified within the tested dose range. The present finding may serve as a reference for AM’s safety profile. Additional research is required to determine the optimal dosage for recurrent intraperitoneal injection of AM.
No takes yet. Share an insight, caveat, or question.
Setyawati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: